Neoadjuvant T-VEC confers durable survival benefits for resectable melanoma
Source: Healio, August 2023
- Patients with resectable melanoma who received T-VEC prior to surgery achieved better 5-year OS than those who underwent surgery alone.
- T-VEC-treated patients also achieved longer recurrence-free survival.
Neoadjuvant talimogene laherparepvec conferred durable benefits for patients with advanced resectable melanoma, according to study results published in JAMA Oncology.
The approach appeared associated with significantly higher rates of OS, RFS and EFS at 5 years.